Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.
The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.Theragnostics inks AstraZeneca agreement
Latest in Radiation Oncology/Therapy
Mevion secures CE Mark for compact proton therapy system
February 25, 2026
ABK Biomedical completes enrollment in IDE study
February 24, 2026
U.S. FDA clears enhancements to Varian's Halcyon radiotherapy system
February 23, 2026
